80890-47-7 Usage
Uses
Used in Cellular Research:
Concanamycin A is used as a lysosomal inhibitor in young and old fibroblasts, helping researchers study the role of lysosomes in cellular processes and aging.
Used in Neurobiological Research:
In the field of neurobiology, Concanamycin A is used as a vacuolar-type H+-ATPase inhibitor in presynaptic vesicles, aiding in the investigation of neurotransmission and synaptic vesicle function.
Used in Hepatocyte Studies:
Concanamycin A serves as a lysosomal acidification blocker in HepG2 hepatocytes, a liver cancer cell line, which is instrumental in research focused on liver function, liver diseases, and cancer cell behavior.
Used in Virology:
In virology, Concanamycin A is utilized to inhibit the acidification of organelles and block cell surface expression of viral envelope glycoproteins without affecting their synthesis, providing insights into viral replication and host-pathogen interactions.
Used in Immunology:
In immunological research, Concanamycin A interferes with intracellular protein trafficking and inhibits perforinand Fas-based lytic pathways in cell-mediated cytotoxicity, which is crucial for understanding immune cell function and the mechanisms of immune responses.
Overall, Concanamycin A is a versatile compound with applications across various scientific disciplines, including cellular research, neurobiology, hepatocyte studies, virology, and immunology, making it an important tool for advancing our understanding of complex biological processes.
Biological Activity
Specific inhibitor of V-type (vacuolar) H + -ATPase that displays > 2000-fold selectivity over other H + -ATPases (IC 50 values are 9.2, > 20000, > 20000 and > 20000 nM for yeast V-type, F-type, P-type H + -ATPases and porcine P-type Na + ,K + -ATPase respectively). Blocks cell surface expression of virus envelope glycoproteins without affecting synthesis and exhibits cytotoxicity in several cell lines.
Biochem/physiol Actions
Concanamycin A (ConA) inhibits acidification of organelles and perforin-mediated cytotoxicity. It is a vacuolar-type v-ATPase inhibitor. ConA possesses antiprotozoal and antineoplastic properties. It mediates inhibition of the negative factor (Nef) protein of the human immunodeficiency virus.
References
1) Nishihara?et al.?(1995),?Specific inhibitors if vacuolar type H(+)-ATPases induce apoptotic cell death; Biochem. Biophys, Res. Commun.,?212?255
2) Hong?et al. (2006),?Nitric oxide production by the vacuolar-type (H+)-ATPase inhibitors bafilomycin A1 and concanamycin A and its possible role in apoptosis in RAW 264.7 cells; J. Pharmacol. Exp. Ther.,?319?672
3) Muroi?et al.?(1993),?Folimycin (concanamycin A), a specific inhibitor of V-ATPase, blocks intracellular translocation of the glycoprotein of vesicular stomatitis virus before arrival to the Golgi apparatus; Cell Struct. Function,?18?139
4) Cashikar and Hanson (1987),?A cell-based assay for CD63-containing extracellular vesicles; PLoS One,?14?e0220007
5) Gradzka?et al.?(2018),?Inhibitor of apoptosis proteins are required for effective fusion of autophagosomes with lysosomes; Cell Death Dis.,?9?529
Check Digit Verification of cas no
The CAS Registry Mumber 80890-47-7 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 8,0,8,9 and 0 respectively; the second part has 2 digits, 4 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 80890-47:
(7*8)+(6*0)+(5*8)+(4*9)+(3*0)+(2*4)+(1*7)=147
147 % 10 = 7
So 80890-47-7 is a valid CAS Registry Number.
InChI:InChI=1/C46H75NO14/c1-13-16-34-28(7)37(58-38-22-33(48)43(31(10)57-38)60-45(47)53)23-46(54,61-34)30(9)41(51)29(8)42-35(55-11)18-15-17-24(3)19-26(5)39(49)32(14-2)40(50)27(6)20-25(4)21-36(56-12)44(52)59-42/h13,15-18,20-21,26-35,37-43,48-51,54H,14,19,22-23H2,1-12H3,(H2,47,53)/b16-13+,18-15+,24-17+,25-20+,36-21-/t26-,27-,28-,29+,30+,31-,32+,33-,34-,35+,37-,38+,39+,40-,41-,42-,43-,46-/m1/s1
